Evidence map›Paper›PMID 28114388›Full record

ArticlePloS one2017

Multicompartmental Pharmacokinetic Model of Tenofovir Delivery to the Rectal Mucosa by an Enema.

Yajing Gao, David F Katz

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Modeling HIV Pre-Exposure Prophylaxis.Frontiers in pharmacology · 2019
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yajing GaoDepartment of Biomedical Engineering, Duke University, Durham, NC, United States of America.
David F KatzDepartment of Biomedical Engineering, Duke University, Durham, NC, United States of America.
Duke University · US

Funding

Tissue pharmacology imaging and modelingU19AI113127 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BUMPUS, NAMANDJE N · 2014 to 2018
$20.7M
Preclinical User Accptability Studies Long Acting Vaginal Gels, Intravaginal RingU19AI077289 · NIAID · IMQUEST BIOSCIENCES · PI BUCKHEIT, ROBERT WALTER · 2008 to 2012
$6.7M
Novel Determination of Microbicide PK in Women's Reproductive HealthR01HD072702 · NICHD · DUKE UNIVERSITY · PI KATZ, DAVID FRANK · 2012 to 2015
$1.8M
NIAID NIH HHS U19 AI077289NIAID NIH HHS U19 AI113127NICHD NIH HHS R01 HD072702
6 · The paper itself

Abstract

Rectal enemas that contain prophylactic levels of anti-HIV microbicides such as tenofovir have emerged as a promising dosage form to prevent sexually transmitted HIV infections. The enema vehicle is promising due to its likely ability to deliver a large amount of drug along the length of the rectal canal. Computational models of microbicide drug delivery by enemas can help their design process by determining key factors governing drug transport and, more specifically, the time history and degree of protection. They can also inform interpretations of experimental pharmacokinetic measures such as drug concentrations in biopsies. The present work begins rectal microbicide PK modeling, for enema vehicles. Results here show that a paramount factor in drug transport is the time of enema retention; direct connectivity between enema fluid and the fluid within rectal crypts is also important. Computations of the percentage of stromal volume protected by a single enema dose indicate that even with only a minute of enema retention, protection of 100% can be achieved after around 14 minutes post dose. Concentrations in biopsies are dependent on biopsy thickness; and control and/or knowledge of thickness could improve accuracy and decrease variability in biopsy measurements. Results here provide evidence that enemas are a promising dosage form for rectal microbicide delivery, and offer insights into their rational design.

Indexed as

EnemaAnti-HIV AgentsHumansIntestinal MucosaModels, TheoreticalReverse Transcriptase InhibitorsTenofovirAnti-HIV AgentsReverse Transcriptase InhibitorsTenofovir

Identifiers

PMID28114388
PMCPMC5256988
OpenAlexW2580563172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.